Deals this week: Adlai, Skyhawk, Aerpio Pharmaceuticals

29th June 2018 (Last Updated June 29th, 2018 00:00)

Adlai Nortye Biopharma has raised $50m through a series B financing round from Yuanming Capital.

Adlai Nortye Biopharma has raised $50m through a series B financing round from Yuanming Capital.

Matrix Partners China, DT Capital, and Yahui Precision Medicine Fund also participated in the funding round.

Based in China, Adlai Nortye is a biopharmaceutical company engaged in the research and development of cancer immunotherapy drugs.

Skyhawk Therapeutics has raised $40m in equity investment in a seed funding round.

The funding round included the participation of biotech-focused funding companies, technology-focused family investment firms, and other major family investors.

The new investment, along with a recently announced $60m collaboration, brings the total capital raised by the company to $100m.

The company plans to use the funds towards the development of its STAR technology platform, as well as drug candidates in the neurological, oncological and immunological areas.

Based in the US, Skyhawk Therapeutics is a drug discovery and development company.

Aerpio Pharmaceuticals has raised $45m through an underwritten public offering of 11.6 million shares of its common stock priced at $3.85 a share.

The underwriters will receive a 30-day option to buy an additional 1.7 million shares of common stock.

The company plans to use the funds towards working capital and general corporate purposes.

Goodwin Procter is the company's legal adviser for the offering.

Based in the US, Aerpio Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialisation of treatments for ocular diseases.

"Skyhawk Therapeutics has raised $40m in equity investment in a seed funding round."

Constellation Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $86.25m through an initial public offering of shares of its common stock.

J.P. Morgan Securities, Jefferies, BMO Capital Markets, and Oppenheimer & Co were appointed as underwriters to the company for the offering.

Based in the US, Constellation Pharmaceuticals is a biopharmaceutical company that develops therapeutics for the treatment of cancer and inflammatory diseases.

Crinetics Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $86.25m through an initial public offering of shares.

The funds are intended to be used towards the clinical development of its non-peptide based agonist, CRN00808. The funds will also be used towards other development programmes, working capital and general corporate purposes.

J.P. Morgan Securities, Leerink Partners and Piper Jaffray & Co were appointed as underwriters to the company for the offering.

Based in the US, Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of drugs.

CEL-SCI has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $11m through a private placement of three million shares.

Based in the US, CEL-SCI is a biotechnology company that develops investigational therapies for cancer and other diseases.

Hart & Hart was appointed as the company's legal adviser for the offering.